
Dogwood Therapeutics fell 81.3% from $5.67 to $1.06, behind the S&P 500's +11.2%. Its worst day was Dec 22 (−25.0%), and its low came Nov 4 at $1.03.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Dogwood Therapeutics closed at its highest level of the year, 20.3% above where the year started.
+6.2% · S&P 500 −1.1%
Story events cover the past 12 months · Times ET
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- The overall study dropout rate of ~4.4% is far below rates typically
−25.0%, the year's worst day · S&P 500 +0.6%
EPS of $-0.26 beat the $-1.00 estimate on $0.00 revenue.
−7.8% · S&P 500 −1.4%
Dogwood Therapeutics shares rose 18.5%, while the S&P 500 rose 2.9%.
+18.5% · S&P 500 +2.9%
Dogwood Therapeutics shares rose 14.6%, while the S&P 500 rose 1.4%.
+14.6% · S&P 500 +1.4%
EPS of $-0.15 beat the $-0.20 estimate on $0.00 revenue.
+6.5% · S&P 500 +0.8%
EPS of $-0.34 missed the $-0.14 estimate on $0.00 revenue.
+2.9% · S&P 500 +0.7%
EPS of $-0.14 beat the $-0.15 estimate on $100,000.00 revenue.
+1.0% · S&P 500 −4.4%
Where it ended: a close of $1.06 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 17, 2027 (EPS est. $-0.15).
Nothing in the past 12 months.
All DWTX analyst actionsNothing in the past 12 months.
All DWTX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DWTX and SPY from Benzinga historical bars. Not investment advice.